Johnson & Johnson (NYSE:JNJ - Get Free Report) shares traded down 0.5% on Monday . The stock traded as low as $151.40 and last traded at $152.58. 1,672,391 shares were traded during trading, a decline of 77% from the average session volume of 7,317,099 shares. The stock had previously closed at $153.40.
Analyst Ratings Changes
JNJ has been the subject of a number of research reports. Royal Bank of Canada restated an "outperform" rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Thursday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, May 6th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 17th. Finally, HSBC upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating and raised their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.86.
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Trading Down 2.1 %
The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The firm's 50-day simple moving average is $152.31 and its 200 day simple moving average is $155.11. The stock has a market capitalization of $364.18 billion, a P/E ratio of 9.48, a PEG ratio of 2.55 and a beta of 0.55.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.68 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.64 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. Johnson & Johnson's payout ratio is 29.68%.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in JNJ. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson in the first quarter worth $31,000. Keener Financial Planning LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $40,000. Tower View Wealth Management LLC grew its position in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock worth $40,000 after acquiring an additional 165 shares in the last quarter. WFA Asset Management Corp raised its holdings in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company's stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Finally, Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $44,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
